Cannell Capital’s Kindred Biosciences KIN Stock Holding History
Bought
Maintained
Sold
Other funds holding KIN
PVAM
Cannell Capital's KIN Position: Q4 2017 in Review
Cannell Capital sold out of Kindred Biosciences (KIN) in Q4 2017, closing a stake of 196,318 shares — an estimated $1.54M sold.
Cannell Capital first reported a position in KIN in Q2 2017 and held it in 2 quarters. The position peaked at $3.27M in Q2 2017. 61 funds tracked by Wall St. Rank hold KIN as of Q4 2017.
- Cannell Capital reported no remaining Kindred Biosciences position as of Q4 2017 after selling out during the quarter.
- Cannell Capital sold 196,318 Kindred Biosciences shares in Q4 2017, an estimated $1.54M.
- Cannell Capital first reported a position in Kindred Biosciences in Q2 2017 and held it in 2 quarters.
- Cannell Capital's Kindred Biosciences position peaked at $3.27M in Q2 2017.
- 61 funds tracked by Wall St. Rank held Kindred Biosciences as of Q4 2017.
Based on Cannell Capital's 13F filing for Q4 2017, filed 14 Feb 2018.